3Q 2025 Earnings Presentation November 6, 2025 1 © 2025 Artivion, Inc. FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management's beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs and expectations about our future revenue ...

Financial Performance - Q1 2026 - Revenue reached $2.308 billion, a 21% increase quarter-over-quarter (QoQ) and a 23% increase year-over-year (YoY)[17] - Non-GAAP Gross Margin was 29.9%, up 3.5 percentage points QoQ but down 9 percentage points YoY[6, 17] - Non-GAAP Diluted Net Income per Share was $1.22, a 321% increase QoQ but a 33% decrease YoY[6, 17] - Adjusted Free Cash Flow was $448 million, a 482% increase QoQ and a 399% increase YoY[6, 17] Revenue by End Market - Q1 2026 - Datacenter revenue was $269 million, a 26% increase QoQ[15] - Edge revenue was $1.387 billion, a 26% increase QoQ[15] - Consumer revenue was $652 million, an 11% increase QoQ[15] Capital Expenditure - Total Sandisk Gross CapEx was $387 million, representing 16.8% of net revenue[18] - Total Sandisk Cash CapEx was $40 million, representing 1.7% of net revenue[18] Fiscal Second Quarter Guidance - Revenue is projected to be between $2.55 billion and $2.65 billion[20] - Non-GAAP Gross Margin is expected to be between 41% and 43%[20] - Non-GAAP Diluted Net Income per Share is projected to be between $3.00 and $3.40[20]

Financial Performance - Q3 2025 revenue reached $80.5 million, supporting the company's full-year guidance[4] - Q3 2025 gross margin improved year-over-year to 37% from 36%, driven by cost optimization initiatives[4] - Net income decreased to $1.7 million in Q3 2025 from $3.4 million in Q3 2024 due to lower revenue[8] - Adjusted EBITDA decreased to $11.0 million in Q3 2025 from $16.3 million in Q3 2024, also due to lower revenue[8] Capital Structure and Share Repurchase - The company refinanced prior debt with a new $90 million revolving credit facility and a $60 million term loan[5] - Approximately $10 million in common shares were repurchased during Q3 2025, bringing the total to approximately $45 million over the past seven quarters[5] Market Position and Product Innovation - Turtle Beach headsets gained market share amidst an improving gaming headset market year-to-date September and in Q3 2025[5] - The company revealed over 40 new gaming accessories since Q2 2025[5] - Turtle Beach products are top-sellers in the broader gaming peripherals market[5] - The company is focused on unlocking potential in the $11 billion gaming accessories market[12] Guidance and Long-Term Targets - The company's 2025 net revenue guidance is $340 million to $360 million, with adjusted EBITDA between $47 million and $53 million[9] - The company's long-term financial targets include revenue growth of 10%+ CAGR, gross margins in the mid-to-high 30s, and adjusted EBITDA margins in the mid-to-high teens[9]

Business Highlights - Codexis secured a $37.8 million Supply Assurance Agreement with Merck [7, 15] - The company expects to receive the cash from the Merck agreement by the end of 2025 [7, 15] - Codexis has a cash runway through 2027 [7] - Codexis has 11 customers this year and a pipeline of 40 prospects [7, 13] - The company will sign a lease on a 34,000 square feet multi-purpose GMP facility in the next few weeks [7] Executive Management Transition and Cost Reduction - Codexis is reducing operating expenses by 25% through the elimination of 46 positions [10] - Dr Stephen Dilly will transition to Chairman, and Dr Alison Moore will assume the role of President and CEO [10] Q3 2025 Financial Results - Total revenue for Q3 2025 was $8.6 million, compared to $12.8 million in Q3 2024 [16] - Product gross margin increased to 64% in Q3 2025 from 61% in Q3 2024 [16] - R&D expenses for Q3 2025 were $13.9 million, compared to $11.5 million in Q3 2024 [16] - Net loss for Q3 2025 was $19.6 million, or $0.22 per share, compared to a net loss of $20.6 million, or $0.29 per share, in Q3 2024 [16]

ibex Q1 FY2026 Earnings Call November 6, 2025 Bob Dechant, CEO Built for what's next. Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts, are forward-looking statements. The words "believe," "estimate," "expect," "may," "will" and similar expressions are intended to identify forward-looking statements. Such forward- looking stateme ...

Business Overview - AvePoint is a one-stop solution for data management, focusing on human-generated data and offering a platform approach in the age of AI[17, 19] - The company operates in an enormous addressable market, estimated at $81.3 billion in 2024 and projected to reach $140 billion by 2028, representing a compound annual growth rate (CAGR) of 14.6%[21] - AvePoint serves a diverse customer base spanning every industry and around the world, with North America contributing 44% of total Annual Recurring Revenue (ARR), EMEA 35%, and APAC 21% as of December 31, 2024[32, 33] Financial Performance - The company has demonstrated rapid topline growth, with total ARR increasing from $214.7 million in 2022 to $327.0 million in 2024, representing a 23% CAGR[35] - AvePoint has improved operating efficiency, with non-GAAP operating margin increasing from (1.2%) in 2022 to 14.4% in 2024, a 1,560 basis points improvement[37] - Total ARR grew 26% year-over-year to $390.0 million in Q3 2025, with net new ARR at a record $22.4 million, growing 19% year-over-year[81] - The company's Q4 2025 financial guidance projects total revenue between $110.0 million and $112.0 million, representing a year-over-year growth of 23% to 26%[106] Strategic Priorities - AvePoint aims to reach $1 billion of ARR by 2029 through solutions, segments, geographies, cross-selling, and partners[75, 77] - The company's strategic priorities include accelerating customer adoption and retention, expanding platform offerings, scaling the channel ecosystem, broadening global presence, and pursuing strategic acquisitions and investments[74] - The company has a track record of successful M&A, including the acquisition of Torsion, Essential, I-Access Solutions, Combined Knowledge, tyGraph and Ydentic[105]

Q3 2025 Earnings N O V E M B E R 2 0 2 5 Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 This presentation contains "forward-looking statements" about Expedia Group's financial performance, operating results, and guidance, which may include, but are not limited to, statements relating to future gross bookings; revenues; expenses; margins and margin expansion, including EBITDA margin expansion; profitability; net income (loss); earnings per share; and other measures of result ...

Financial Performance Highlights - Aggregate Subscriber Value reached $1.6 billion in 2Q25, a 40% year-over-year increase[7] - Contracted Net Value Creation was $376 million in 2Q25, a 316% year-over-year increase[7] - Cash Generation was $27 million in 2Q25, marking the fifth consecutive quarter of positive cash generation[8] - Trailing four-quarter Cash Generation totaled $119 million[9] - Contracted Net Earning Assets, inclusive of net debt, stood at $3.0 billion as of June 30, 2025, or $13.03 per share[9] - Upfront Net Subscriber Value exceeded $5.7k, representing an 11% margin, expanding 17 percentage points year-over-year[10] Operational Metrics - Customer Additions grew 15% year-over-year in Q2[14] - Customer Additions with Storage grew 50% year-over-year in Q2, with a Storage Attachment Rate reaching 70%[14] - Net Subscriber Value increased to a record high of $17,004, a 22% year-over-year increase[48] - Aggregate Subscriber Value increased 40% year-over-year to $1.6 billion, while Aggregate Creation Costs increased 11% to $1.1 billion[59] Home-to-Grid Distributed Power Plant - Over 71,000 customers are enrolled in grid service programs, representing a growth of over 300% year-over-year[17] - Sunrun delivered 354 MW of power during dispatches over the last year[16] - Networked Storage Capacity reached 3.2 GWhr[16] - Sunrun expects to have over 10 GWhrs of dispatchable capacity online by 2029[17] Investment Tax Credit (ITC) - The 48E Investment Tax Credits (ITC) are maintained for the storage portion of projects through 2033 at 30%+, while ITCs for the solar portion are maintained through 2027[23] - Subscriptions represented 94% of Sunrun's 2Q25 volume[27]

Financial Performance - Net income available to shareholders for the three months ended September 30, 2025 was $453 million[9], compared to $150 million for the same period in 2024[9] - Adjusted earnings for the three months ended September 30, 2025 were $970 million[9], compared to $767 million for the same period in 2024[9] - Adjusted earnings, less notable items, for the three months ended September 30, 2025 were $261 million[9], compared to $243 million for the same period in 2024[9] - Book value per common share as of September 30, 2025 was $8160[9], while book value per common share, excluding AOCI, was $15194[9] Segment Performance (Three Months Ended September 30, 2025) - Annuities adjusted earnings were $304 million[16] - Life adjusted earnings were $40 million[16] - Run-off adjusted earnings were $641 million[16] - Corporate & Other reported an adjusted loss of $15 million[16] Key Metrics - Combined total adjusted capital was $54 billion as of September 30, 2025[9] - Combined risk-based capital ratio was between 435% and 455% as of September 30, 2025[9]

Pemvidutide's Potential in Liver Diseases - Pemvidutide targets both liver and metabolic components with a differentiated 1:1 glucagon/GLP-1 ratio, showing potential in various steatotic liver diseases[10] - The IMPACT Phase 2b trial of Pemvidutide in MASH patients showed promising 24-week data, with 48-week data and an FDA meeting expected in Q4 2025[14] - Pemvidutide demonstrated a favorable tolerability profile with no dose titration, and a low rate of AEs leading to treatment discontinuation (1.2% in the 1.8 mg group)[55] MASH (NASH) Market and Clinical Data - The IMPACT Phase 2b trial enrolled 212 subjects with MASH (F2/F3), liver fat content ≥ 8%, and BMI ≥ 27.0 kg/m2, HbA1c < 9.5%[23] - Pemvidutide shows potential for best-in-class MASH resolution without worsening of fibrosis[24] - IMPACT data shows significant weight loss at 24 weeks, addressing an underlying cause of MASH[48] - In a Phase 2 obesity study, Pemvidutide demonstrated a lean loss ratio of 21.9% at 48 weeks, indicating class-leading lean mass preservation[52] AUD and ALD Programs - The RECLAIM Phase 2 trial enrollment for AUD is expected to be completed in Q4 2025, while the RESTORE Phase 2 trial for ALD was initiated in Q3 2025[14] - Approximately 66% of AUD patients have obesity or overweight, similar to ALD patients, making them potential targets for Pemvidutide treatment[60] - ALD patients are approximately 3 times more likely to have liver-related disease progression compared to MASH patients[65] Financial Position - The company reported $211 million in total cash as of September 30, 2025, with access to a $125 million credit facility[75] - The company's 9-month year-to-date operating expenses (OPEX) were $54.5 million[75]